Skip to main
NVCR

Novocure (NVCR) Stock Forecast & Price Target

Novocure (NVCR) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 20%
Hold 60%
Sell 0%
Strong Sell 0%

Bulls say

NovoCure is a promising player in the oncology market with its flagship product, Optune, and multiple upcoming catalysts including potential advancement in pancreatic cancer therapies. Their strong clinical data and collaborations in the pipeline, along with anticipated FDA approvals, support our Buy rating and $46 price target through 2038. Risks to achievement include IP protection, competition, and safety or efficacy concerns, though the recently reported TRIDENT trial reaffirms the overall strong performance of TTFields therapy in glioblastoma.

Bears say

NovoCure is showing strong revenue growth from its Tumor Treating Fields (TTFields) devices, but this growth is largely driven by one-time revenue benefits and early launches of new products. Furthermore, competition from other oncology companies, particularly in the lung cancer market, may limit future growth potential. Additionally, NovoCure's financials show a decreasing trend in operating expenses, but there are still risks in the form of safety signals and regulatory concerns with their pipeline assets.

Novocure (NVCR) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 20% recommend Buy, 60% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novocure (NVCR) Forecast

Analysts have given Novocure (NVCR) a Buy based on their latest research and market trends.

According to 5 analysts, Novocure (NVCR) has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novocure (NVCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.